Kevin

$IBRX The shorts are desperately trying to push this stock down in order to cover their positions quickly before it blows up in their faces, in my opinion. Too many bullish stories coming out now to keep this stock from continuing its trend higher. We alerted #IBRX as our 2026 Wealth Builder Spec Stock to our subscribers at $2.06 a share in early January. It’s $8 a share now. This is the 1st inning. Flag this post and hit me up on 01/01/27.

$IBRX Listen to THIS! According to Fox Business, the reason for Makary's resignation may have been related to Sen. Ron Johnson wanting answers about FDA's arbitrary rejection of cancer drugs/immunotherapies!

@MaryBowdenMD Exactly. He will not be missed.

Under Marty Makary, 7 million children received a mRNA shot for a cold.

@calleymeans Any good he might have done is tainted by his Covid vaccine history and interference or lack of interest in getting Anktiva from ImmunityBio approved when the studies show it should be a front-line therapy.

Marty is one of the highest integrity, highest energy, highest IQ people and I’ve ever met. He got more done in a year than any previous FDA commissioner has done in their careers - including re-invigorating the “food” part of the FDA with Kyle.

$IBRX For those that don't have a Bloomberg subscription, here (archive.is/0fJHq)is a free link to the Bloomberg article from Dec 3rd 2025 that discusses Wisconsin Senator Ron Johnson's relationship with PSS and the reason he wanted to attend the FDA meeting on Anktiva. If the Fox news report is true, that Johnson was instrumental in getting Makary terminated, then this news is HUGE and very beneficial to $IBRX. Johnson and PSS are very close and have met numerous times to discuss this situation. Both President Trump and Senator Johnson are Champions of the "Right to Try" movement (ronjohnson.senate.gov/right-to-try). The FDA stonewalling IBRX and others should be a thing of the past, now that both Makary and Prasad are out!

@thegarybrecka Approve Anktiva from ImmunityBio so that cancer families don’t have to travel to other countries to get this life-saving therapy. Just read and view the studies. It’s there in black and white. This should be a frontline therapy for cancer and all other diseases.

🚨 BREAKING: A new era at the FDA officially begins today. Kyle Diamantas has been named Acting Commissioner of the FDA. Before stepping into this role, Kyle served as the FDA’s Deputy Commissioner for Human Foods, overseeing nutrition policy, food safety, inspections, and federal emergency response across the country. Why does this matter? Because the FDA Commissioner influences nearly every aspect of your health and your family’s future, from what ingredients are allowed in your food to how drugs and treatments get approved. This is one of the most powerful health positions in the United States. For decades, Americans have watched chronic disease rise, food quality decline, and trust in the system erode. People are paying attention now. The question is: What is the FIRST thing you want to see addressed?

@gainzalgo Agreed… 👍

$IBRX This is an interesting angle. Dr Pat already had Calley Means on Cancer Decoded talking about how broken the current cancer treatment system is, especially for patients who get stuck with chemo, radiation, more chemo, and no real path forward. Now you have a White House health circle that seems much more open to MAHA, Right to Try, and pushing beyond the old treatment playbook. Not saying anything is guaranteed, but if the FDA climate starts shifting toward faster access for serious unmet needs, IBRX is exactly the kind of immunotherapy story that could benefit. Dr Pat has been way too visible internationally lately for this to feel random.

$IBRX No RTF from the FDA after the 60-day review window following Anktiva’s March resubmission is a strong sign the filing was accepted for full review. Strong data + major unmet need = very promising setup ahead.

@DustinHuntwn IBRX

What’s your #1 stock for today?

@SecKennedy Such high praise for someone about to be fired. Tell that to the cancer families that have to travel to the 30+ countries to get Anktiva from ImmunityBio that was created in the U.S.

Marty, you took on entrenched interests, challenged the status quo, and never lost sight of the American people we serve. You pushed forward critical reforms and helped advance our mission to Make America Healthy Again. I’m grateful for your courage and your friendship. Wishing you the very best in your next chapter. I also want to thank Kyle Diamantas for stepping in as Acting Commissioner — his leadership has already delivered remarkable wins on the MAHA food agenda, and I have full confidence in his continued work. We have an outstanding team at FDA, and the work continues without pause. The search for a new Commissioner is already underway, and we will move forward with urgency.

Had to repost this paper that the FDA knew and even published a report that patients with lung cancer who failed all standards of care die early because of lymphopenia. When T cell and NK cell count is increased progression is delayed and overall survival increases. Stay tuned.

JUSTICE IS FINALLY HERE After 14 years on the run, Poul Thorsen — the researcher behind the CDC’s cornerstone “no autism link” study — has been extradited from Germany and is now in U.S. custody. Facing 22 felony counts of wire fraud and money laundering for stealing over $1 MILLION in CDC grant money meant for autism research. The same study used for years to tell parents “there’s no link”… written by a man who was allegedly embezzling taxpayer dollars while helping shape vaccine policy. This isn’t just one bad actor. This is the foundation of the “safe and effective, no questions asked” narrative cracking wide open. Parents were mocked, censored, and denied justice for too long. No more. We demand informed consent, medical freedom, and parental rights. Our children’s health should never be dictated by compromised science and government agencies that refuse to clean house… *Post including comments are compliments of Michigan for Vaccine Choice on FB

The complexity of an AI driven robot that needs to meet GMP standards & learn complex steps of targeted cell manufacture. A marvel and the first robot of its kind in the world. Can’t wait till we lift off the first patient’s NK cells in LA from NANT LEONARDO. Unstoppable scale.

Proud to be an investor in this company We’ll save millions and potentially billions of lives with Anktiva Interleukin-15 is the most important platform of the decade

$IBRX Praying for strength, healing, and a miracle for this brave young fighter. No child should have to battle cancer alone. Wishing him and his family hope, courage, and better days ahead.

Excellent overview….. “Why Lynch syndrome and prostate active surveillance, simultaneously? Both populations have cells that are not yet cancer but are accumulating the errors of cancer. Lynch carriers cannot repair DNA mismatches; their premalignant cells display abnormal proteins for decades. Active-surveillance prostate patients have organ-confined low-grade tumors that may or may not progress over years. In neither case is the question how to kill cancer. The question is how to keep abnormal cells from becoming cancer that has gone too far to control. That is what IL-15 does. It expands NK cells, the innate first responders. It expands memory CD8+ T cells, the adaptive surveillance arm. It does so without expanding the regulatory T cells that would suppress the response. Both arms of the immune system at higher activity, in populations whose cells are already trying to become cancer. The hypothesis is interception. Catch the cells before they cross into cancer.” ————————- “IL-15 was ranked #1 of 124 immunotherapy agents by the NCI in 2007. The grants did not follow. ANKTIVA was approved by the FDA in 2024. This week the NCI put its name on two cancer-prevention-and-early-intervention trials of the molecule. One on a Thursday. One on a Friday. In the prostate trial, the NCI is putting its own vaccine alongside the drug. Both trials are NCI-sponsored. The federal government is paying to find out whether the immune system can be taught to stop cancer before it starts. Same institution. Three different decades. Fifty-seven years between drawing the blood and sponsoring the prevention. The work did not move. The institution did.”

$IBRX Somewhere in a genetic counselor's office today, a 25-year-old is being told the result of her test. She has Lynch syndrome. Her lifetime risk of colorectal cancer is closer to 80% than 5%. Her risk of endometrial cancer is 40 to 60%. There are six other organs the same mutation will try to kill her in. The counselor will tell her to schedule a colonoscopy every year for the rest of her life starting now. He will tell her about risk-reducing hysterectomy and oophorectomy starting around age 40. He will mention aspirin. He will not tell her about a preventive drug. Because there isn't one. THE NUMBERS Lynch syndrome is caused by germline mutations in DNA mismatch repair genes. The mutation is inherited. Every cell of every body part carries it. About one in 279 Americans is a carrier. Roughly 1.2 million people. Most do not know. Lifetime cancer risks for the carriers: - Colorectal cancer: 50 to 80% - Endometrial cancer in women: 40 to 60% - Stomach, ovarian, hepatobiliary, urinary, small bowel, brain - Average age at colorectal cancer diagnosis: 44 General population colorectal risk: 4 to 5%. Standard of care is not prevention. It is surveillance. For the highest-risk genes (MLH1, MSH2), annual colonoscopy starting between ages 20 and 25. Find the cancer earlier than it would otherwise be found. Cut it out before it spreads. The only preventive intervention with randomized-trial evidence is daily aspirin (CAPP2, Burn et al, Lancet, 2011). 600 mg per day for a mean of 25 months. Per-protocol hazard ratio of 0.41 for colorectal cancer. Real but modest. A single anti-inflammatory tablet, repurposed. That is the field. Until this week. THE BURIED LINE ImmunityBio filed its Q1 2026 quarterly report with the SEC on May 7. Dozens of pages of pipeline disclosures, financial statements, legal proceedings. In the middle of one MD&A pipeline list, one sentence appears: "ANKTIVA has been selected by the NCI for evaluation in a cancer prevention study in patients with Lynch syndrome." That is one line in a federal SEC filing. THE NEXT DAY On May 8, one day after the 10-Q was filed, a new entry was posted to clinicaltrials.gov. Trial NCT07574541. Phase 2. Sponsor: National Cancer Institute. Setting: NIH Clinical Center, Bethesda. Population: men with low- and intermediate-risk prostate cancer on active surveillance. The intervention: an NCI-developed three-antigen vaccine (PSA, MUC-1, brachyury) plus N-803. N-803 is the generic name for ANKTIVA. The NCI is putting its OWN vaccine alongside ANKTIVA in men whose tumors haven't progressed to radical therapy yet. Running it at its OWN clinical center in Bethesda. With ITS OWN budget. ImmunityBio supplies the drug. The taxpayers pay for the test. Primary endpoint: CD8+ and CD4+ T-cell density inside the tumor before and after treatment. Two NCI-sponsored ANKTIVA trials in two days. Both about catching cancer earlier or stopping it from progressing. That makes three NCI-sponsored programs total: the two new ones plus the rBCG Expanded Access Program disclosed in the company's most recent annual 10-K. THE FIRST ACT, 1969 The institution behind both new trials is the National Cancer Institute. The same NCI. In 1969, a Hungarian-born physician named Joseph Sinkovics, working at MD Anderson Hospital, drew his own blood. He isolated the lymphocytes. He watched them kill cultured cancer cells in a petri dish. He photographed it. He sent the photos and the data to the NCI. They cancelled his grant. They called the killing "an in vitro artifact." They were wrong. The cells he had photographed were what would later be named natural killer cells, formally classified by Kiessling, Klein, and Wigzell in 1975. The NCI in 1969 said: this is not real. THE SECOND ACT, 2007 In 2007, the same NCI hosted a workshop on cancer immunotherapy agents. Co-sponsored with NIH, FDA, AACR, ASH. They reviewed 124 immunotherapy agents. They ranked them by potential to impact cancer mortality. The molecule ranked #1 was interleukin-15. IL-15. The cytokine that activates the very NK cells the agency had rejected as artifacts thirty-eight years earlier. The NCI in 2007 said: this is the most important cancer molecule we know of. The grants did not follow. Seventeen more years passed. THE THIRD ACT, 2026 In 2024, the FDA approved the first IL-15 superagonist for human use. ANKTIVA. The molecule that activates NK cells. The molecule the NCI had ranked first seventeen years earlier. This week, the same NCI selected the same molecule for two trials in two days. Lynch syndrome on Thursday. Prostate active surveillance on Friday. Not treatment of advanced disease in either case. The category is what's new: catch cancer before it forms, or before it converts from manageable to lethal. The NCI in 2026 says: we want to test whether this molecule can keep cancer from progressing in the first place. And we want to test it in two diseases at once. Same agency. Three acts. Fifty-seven years. THE BIOLOGY Why Lynch syndrome and prostate active surveillance, simultaneously? Both populations have cells that are not yet cancer but are accumulating the errors of cancer. Lynch carriers cannot repair DNA mismatches; their premalignant cells display abnormal proteins for decades. Active-surveillance prostate patients have organ-confined low-grade tumors that may or may not progress over years. In neither case is the question how to kill cancer. The question is how to keep abnormal cells from becoming cancer that has gone too far to control. That is what IL-15 does. It expands NK cells, the innate first responders. It expands memory CD8+ T cells, the adaptive surveillance arm. It does so without expanding the regulatory T cells that would suppress the response. Both arms of the immune system at higher activity, in populations whose cells are already trying to become cancer. The hypothesis is interception. Catch the cells before they cross into cancer. THE SHIFT Cancer treatment has been the focus of nearly all immunotherapy development since checkpoint inhibitors arrived in 2011. The Cancer Moonshot, launched in 2016 and revived in 2022, was framed as a mortality-reduction effort. Most of the actual funding went to treatment trials. ANKTIVA in Lynch syndrome would be the first IL-15 superagonist tested in true cancer prevention. ANKTIVA in active-surveillance prostate cancer is the first IL-15 superagonist tested in early intervention, keeping low-grade disease from converting to surgery or radiation. If either works, the category changes. The question becomes whether immune-restoration drugs deserve a place alongside vaccines in cancer prevention and alongside watchful waiting in early intervention. THE STAKES About 1.2 million Americans carry a Lynch syndrome mutation. Most do not know they carry it. Of those who do, the standard offering is annual colonoscopy, risk-reducing hysterectomy and oophorectomy around age 40, daily aspirin. The American Cancer Society projects 333,830 American men will be diagnosed with prostate cancer in 2026. Hundreds of thousands are on active surveillance at any given time. Roughly 35% of those men progress to radical therapy (surgery or radiation) within five years because their tumor grows. The 25-year-old in the genetic counselor's office today has nothing to take. The 65-year-old on prostate active surveillance today is told to wait and watch. This week, the NCI placed its name on the trials that ask whether something different is possible. Twice. THE INSTITUTION RETURNED NK cells were photographed in 1969. The NCI called the killing an artifact. IL-15 was ranked #1 of 124 immunotherapy agents by the NCI in 2007. The grants did not follow. ANKTIVA was approved by the FDA in 2024. This week the NCI put its name on two cancer-prevention-and-early-intervention trials of the molecule. One on a Thursday. One on a Friday. In the prostate trial, the NCI is putting its own vaccine alongside the drug. Both trials are NCI-sponsored. The federal government is paying to find out whether the immune system can be taught to stop cancer before it starts. Same institution. Three different decades. Fifty-seven years between drawing the blood and sponsoring the prevention. The work did not move. The institution did.

Democrat Congressman Ro Khanna from Silicon Valley just got hit with a massive 239-page ethics complaint exposing how his family made up to 108 million dollars in suspicious stock trades beating the market by 28 million while he sat on key defense and healthcare committees. They timed buys in defense stocks like Boeing Lockheed and Palantir right before big bills passed and drug stocks right before FDA decisions with thousands of trades hidden through family trusts and his wife not even using a real blind trust. Late filings galore same-day insider moves and lobbyist connections all while he pretends to be Mr Clean. This is the swamp at its finest Democrats in Congress getting filthy rich off insider info while pushing their agenda against Trump. President Trump has been exposing this corruption for years and now with real accountability coming these crooks are finally getting the heat they deserve. Drop a comment if you want Khanna investigated by DOJ and kicked out of Congress. Repost if youre sick of these career politicians enriching their families on our dime. @AmericaPulseNew #RoKhannaExposed #CongressionalCorruption #DrainTheSwamp #TrumpWasRight #MAGA #AmericaFirst #Trump

Food and Drug Administration Commissioner Marty Makary to leave Trump admin: Reports justthenews.com/politics-polic… via @JustTheNews